EUROAPI SA

What they make

1 input EUROAPI SA supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Concentration2023

  EUROAPI SA was spun off from Sanofi SA in May 2022 as a standalone publicly-listed API company on Euronext Paris — carrying the API manufacturing legacy that Sanofi inherited from the 1999 merger of Hoechst (Germany) and Rhône-Poulenc (France) to form Aventis, which was then acquired by Sanofi in 2004. The API manufacturing know-how that EUROAPI carries includes chemistry established under the German Hoechst and French Rhône-Poulenc pharmaceutical empires — including prostaglandin synthesis expertise developed for ophthalmology and fertility treatments. EUROAPI's prostaglandin API capability at Tours, France is part of a chemical knowledge lineage dating to mid-20th century European pharmaceutical chemistry programs. Within 2 years of its 2022 IPO, EUROAPI faced severe financial difficulties (revenue guidance cuts, earnings shortfalls) and announced major restructuring in 2024 — raising questions about the long-term viability of European small-molecule API manufacturing as a standalone public company against Asian cost competition. The last significant European prostaglandin API manufacturer is under financial stress 2 years after being spun off to 'protect' European pharmaceutical sovereignty.

  EUROAPI SA ↗

• Did you know2023

  EUROAPI manufactures APIs for two completely different disease areas from the same European complex chemistry manufacturing infrastructure: (1) Glaucoma/ocular hypertension — prostaglandin analogue APIs (latanoprost, travoprost, bimatoprost) for eye drops that lower intraocular pressure; glaucoma is the leading cause of irreversible blindness; EUROAPI's Frankfurt site supplies ~22% of branded prostaglandin API for global ophthalmologists; (2) Malaria — artemisinin and semi-synthetic artemisinin derivative APIs for ACT (artemisinin-based combination therapy); artemisinin was discovered by Tu Youyou (Nobel Prize 2015) from traditional Chinese medicine and is now the primary anti-malarial treatment globally; EUROAPI inherited Sanofi's artemisinin supply chain. A European company created as a response to COVID-era supply chain concerns simultaneously supplies the API for preventing blindness in Western patients with glaucoma AND the API for treating malaria in tropical disease patients. High-income country ophthalmology and low-income country malaria treatment share the same European manufacturing network.

  EUROAPI S.A. ↗

• Origin2023

  EUROAPI S.A. was created in May 2022 when Sanofi spun off its active pharmaceutical ingredient manufacturing network as an independent publicly listed company (Euronext Paris: EAPI). The spinoff was explicitly framed as a European industrial policy initiative: European governments and the EU Commission had been alarmed by Europe's dependence on Asian (primarily Chinese and Indian) API suppliers, highlighted dramatically by supply disruptions during COVID-19. EUROAPI was positioned as a 'European pharmaceutical sovereignty champion' — keeping complex API manufacturing expertise within Europe and creating a CDMO that could accept external customers without the conflicts of being a Sanofi subsidiary. Sanofi spun out ~EUR 900M of API revenue into a standalone entity; Sanofi retained a majority stake. EUROAPI inherited 6 European manufacturing sites in France, Germany, Hungary, Italy, and Spain, with expertise in multi-step complex synthesis — prostaglandin chemistry, natural product extraction, opiate alkaloid processing, and fluorinated compound synthesis.

  EUROAPI S.A. ↗